Kuros Biosciences AG

SWX:KURN Stock Report

Market Cap: CHF 773.4m

Kuros Biosciences Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of KURN?
Owner TypeNumber of SharesOwnership Percentage
Institutions6,707,90817%
Individual Insiders10,289,42226.1%
General Public22,461,45756.9%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 42.55% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
23.8%
C. Oomen
9,403,779CHF 184.3m0%no data
3.26%
BlackRock, Inc.
1,287,542CHF 25.2m0%no data
2.88%
UBS Asset Management AG
1,136,067CHF 22.3m0%no data
2.69%
Global Fund Advisors Limited
1,060,233CHF 20.8m0%80.6%
1.82%
Deka Investment GmbH
718,800CHF 14.1m0%0.01%
1.8%
Joh. Berenberg, Gossler & Co. KG
710,775CHF 13.9m0%0.75%
1.13%
Joost de Bruijn
445,486CHF 8.7m0%no data
0.98%
ODDO BHF Asset Management SAS
388,406CHF 7.6m0%0.12%
0.84%
Clemens van Blitterswijk
330,432CHF 6.5m0%no data
0.73%
Janus Henderson Group Ltd.
287,571CHF 5.6m0%no data
0.44%
Valiant Bank AG
172,839CHF 3.4m3.08%0.24%
0.25%
Albert Arp
98,350CHF 1.9m0%no data
0.23%
Causeway Capital Management LLC
90,436CHF 1.8m-5.07%0.01%
0.23%
3V Asset Management AG
90,000CHF 1.8m0%0.92%
0.22%
WCM Investment Management, LLC
87,618CHF 1.7m-9.15%no data
0.21%
American Century Investment Management Inc
82,880CHF 1.6m0%no data
0.18%
Lombard Odier Asset Management (Switzerland) SA
71,205CHF 1.4m578%0.02%
0.14%
Deutsche Asset & Wealth Management
57,174CHF 1.1m0%no data
0.14%
Eaton Vance Management
53,953CHF 1.1m0%no data
0.12%
Lupus alpha Investment GmbH
47,000CHF 921.2k0%0.25%
0.1%
Rhenman & Partners Asset Management AB
40,707CHF 797.8k0%0.08%
0.098%
State Street Global Advisors, Inc.
38,830CHF 761.1k7.79%no data
0.089%
Union Bancaire Privée, UBP SA
35,224CHF 690.4k0%0.01%
0.079%
Charles Schwab Investment Management, Inc.
31,047CHF 608.5k-17.6%no data
0.064%
Swiss Life Asset Management AG
25,242CHF 494.7k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/08 18:04
End of Day Share Price 2026/07/08 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kuros Biosciences AG is covered by 2 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Volker BosseBaader Helvea Equity Research
Thomas MeyerBaader Helvea Equity Research